Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A randomized, noninferiority clinical trial of Single-Shot Intrathecal Morphine versus Continuous Wound Infiltration for postoperative pain control after open pancreatoduodenectomy.

The British journal of surgery·2026
Same author

Real-World Application of a Machine Learning-Based Early Recurrence Model for Guiding Adjuvant Chemotherapy Use in Patients with Gallbladder Cancer.

Gut and liver·2026
Same author

Feasibility of [<sup>99m</sup>Tc]Tc-Mannosylated Human Serum Albumin for Lymphoscintigraphy: A Phase 1/2 Clinical Trial.

Nuclear medicine and molecular imaging·2026
Same author

Prenatal PFAS Exposure in a Twin Pregnancy Cohort: Associations with Thyroid Disruption, Placental Malperfusion, and Fetal Growth Restriction.

Environmental science & technology·2026
Same author

First-in-Human Imaging Results of PHAROS: A Versatile High-Resolution TOF/DOI PET Scanner for Brain, Breast, and Extremity Imaging.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Outcomes and Prognostic Factors in Hepatopancreatoduodenectomy.

Yonsei medical journal·2026

Related Experiment Video

Updated: Jun 17, 2026

Bioluminescent Orthotopic Model of Pancreatic Cancer Progression
09:25

Bioluminescent Orthotopic Model of Pancreatic Cancer Progression

Published on: June 28, 2013

26.8K

Metabolic response during preoperative chemotherapy can predict prognosis in pancreatic cancer.

Won-Gun Yun1, Tae Young Kim2, Seulah Park1

  • 1Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.

Journal of Hepato-Biliary-Pancreatic Sciences
|February 28, 2025
PubMed
Summary
This summary is machine-generated.

Metabolic response on PET scans after preoperative chemotherapy predicts pancreatic cancer outcomes. Patients showing a significant decrease in maximum standardized uptake value (SUVmax) had better survival and lower recurrence rates.

Keywords:
fluorodeoxyglucose F18induction chemotherapyneoadjuvant therapypancreatic neoplasmspositron‐emission tomography

More Related Videos

Robot-Assisted Radical Antegrade Modular Pancreatosplenectomy Including Resection and Reconstruction of the Spleno-Mesenteric Junction
12:34

Robot-Assisted Radical Antegrade Modular Pancreatosplenectomy Including Resection and Reconstruction of the Spleno-Mesenteric Junction

Published on: January 3, 2020

16.5K
An Orthotopic Resectional Mouse Model of Pancreatic Cancer
07:17

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

Published on: September 24, 2020

10.3K

Related Experiment Videos

Last Updated: Jun 17, 2026

Bioluminescent Orthotopic Model of Pancreatic Cancer Progression
09:25

Bioluminescent Orthotopic Model of Pancreatic Cancer Progression

Published on: June 28, 2013

26.8K
Robot-Assisted Radical Antegrade Modular Pancreatosplenectomy Including Resection and Reconstruction of the Spleno-Mesenteric Junction
12:34

Robot-Assisted Radical Antegrade Modular Pancreatosplenectomy Including Resection and Reconstruction of the Spleno-Mesenteric Junction

Published on: January 3, 2020

16.5K
An Orthotopic Resectional Mouse Model of Pancreatic Cancer
07:17

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

Published on: September 24, 2020

10.3K

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiomics

Background:

  • Pancreatic cancer treatment requires reliable markers for preoperative chemotherapy effectiveness.
  • Current indicators for assessing treatment response are limited.
  • Metabolic response evaluation using fluorine-18-fluorodeoxyglucose positron emission tomography (FDG-PET) offers a potential prognostic tool.

Purpose of the Study:

  • To evaluate the prognostic value of metabolic response, assessed by changes in maximum standardized uptake value (SUVmax) on FDG-PET, in patients with pancreatic cancer undergoing preoperative chemotherapy.
  • To determine if metabolic response can predict overall survival, recurrence rates, and pathologic complete response after surgery.

Main Methods:

  • A cohort of 210 pancreatic cancer patients who received preoperative chemotherapy and curative surgery between 2013 and 2022 was analyzed.
  • Metabolic response was categorized using maximally selected rank statistics based on percentage change in SUVmax: responder (>75% decrease), stable disease (15%-75% decrease), and non-responder (≤15% decrease).

Main Results:

  • Metabolic responders (15.7%) demonstrated significantly longer median overall survival (83.0 months) compared to stable disease (66.7%, 51.0 months) and non-responders (11.6%, 32.0 months).
  • Metabolic response was an independent predictor of lower recurrence rates (HR 0.46) and higher odds of achieving pathologic complete response (OR 13.39).

Conclusions:

  • Metabolic response assessed by FDG-PET during preoperative chemotherapy is a valuable predictor of post-resection prognosis in pancreatic cancer.
  • Changes in SUVmax provide critical information regarding treatment effectiveness and residual tumor status, aiding in patient management.